NICE guidance for access to advanced breast cancer treatment

NICE has published draft guidance today recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) as an option for treating HER-positive unresectable or metastatic breast cancer in adults, after two or more anti-HER2 therapies.

The decision means it will be the first time trastuzumab deruxtecan (also called Enhertu) has been commissioned for use in any European country. Up to 400 people will have immediate access to the treatment while more data is collected showing how much longer people who are taking it live, compared with people taking chemotherapy.

There is currently a lack of clinical trial data directly comparing trastuzumab deruxtecan with chemotherapy. However, the committee concluded that data from ongoing trials of trastuzumab deruxtecan and from NHS practice would help address the uncertainty about clinical effectiveness. Trastuzumab deruxtecan is therefore recommended for use in the Cancer Drugs Fund.

Current treatment for HER2‑positive unresectable or metastatic breast cancer includes anti‑HER2 therapies. After two or more anti‑HER2 therapies, the standard care is chemotherapy (such as capecitabine, vinorelbine or eribulin).

Meindert Boysen, Deputy Chief Executive and Director of the Centre for Health Technology Evaluation at NICE, said: “Unfortunately there is no cure for breast cancer that has spread to other parts of the body or that can’t be removed surgically.

The committee heard from patient experts who explained that, because of its side effects, people want to avoid having chemotherapies for as long as possible.

“Trastuzumab deruxtecan is a promising new treatment that has the potential to increase the length of time before the disease gets worse and how long people live overall.

"We’re therefore pleased that our work has allowed a deal to be struck between the company and NHS England supporting access to trastuzumab deruxtecan as an option in the CDF for people with this type of breast cancer.”

NHE July/August 21

NHE July/August 21

Prioritising staff wellbeing

NHE’s July/August 2021 edition focuses on some of the key, defining aspects of a successful, supported health service: Mental Health & Workforce. Elsewhere, we take on the incredibly topical Infection Prevention and address the role which Pharma will play in both our NHS and wider health environment.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Net-Zero NHS

As was outlined by Sir Simon Stevens when the NHS announced their green plans back in 2020, 5,700 lives could be saved each year by improved air quality. Even more could see their overall health improve and be in a position to self-manage their conditions, rather than requiring NHS treatment. Covid-19 has already left the NHS with a sizeable treatment backlog, so anything which can be done to improve patient health and reduce demand is beneficial for all.

Working together, we can help the NHS realise its green ambitions as per the Net-Zero National Health Service report and its ambitious 2040 target. Join us on August 25, 2021 for our Net-Zero NHS event, where we will be joined by health sector leaders and innovators for a day of sharing best practice and networking.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all